^
Association details:
Biomarker:ZG16B expression
Cancer:Ovarian Cancer
Drug:ulenistamab (PBP1510) (ZG16B inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

44P - PAUF as a target for treatment of high PAUF-expressing ovarian cancer

Published date:
10/16/2023
Excerpt:
Furthermore, the administration of an anti-PAUF antibody exhibited notable sensitizing and synchronizing effects on docetaxel in mice bearing the OVCAR-5 xenograft tumors, the docetaxel + anti-PAUF antibody combination group showed the most potent anti-tumor efficacy demonstrated as a nearly 5-fold improved survival in this group (HR: 0.22, 95% CI: 0.09 to 0.54), compared to the control group...Taken together, this study shows that the expression level of PAUF is an independent factor determining malignant behaviors of ovarian cancer and, for the first time, it suggests that PAUF may be a promising therapeutic target for high PAUF-expressing ovarian cancer. The anti-PAUF antibody used in this study, PBP1510...
Secondary therapy:
docetaxel